fda glp-1 compounding crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The New York Times spotlighted

Orforglipron vs injections: Which is better for weight loss and diabetes

PrecisionLife and Ovation are developing a test to predict GLP-1 drug response, enabling precision prescribing and sustainable access to these therapies.

So you're telling me you'd rather lose bone density than change your nutrition, lifestyle and exercise habits

However, that is not the reality: even diabetic patients treated with GLP-1 RAs are more likely to stop them than other second-line anti-diabetic medicines.3 That study didnt report why 50% of diabetics on GLP-1 RAs discontinued them, but gastrointestinal (GI) adverse events were a suggested cause.3 Adverse events are just one of a number of reasons that people stop using these drugs, as follows.

However, there's good evidence that a placebo provides very similar p...

AKKERMANSIA PROBIOTIC SUPPLEMENT: Next-Gen digestive support with our Akkermansia probiotic delivering Akkermansia 2 Billion AFU per serving